{"title": "GLP-1 receptor agonist", "page_id": 21066354, "revision_id": 1120064067, "revision_timestamp": "2022-11-04T23:01:26Z", "content": "{{Short description|Agonist of the GLP-1 receptor used in the treatment of type 2 diabetes}}\n'''[[Glucagon]]-like peptide-1 receptor agonists''', also known as '''GLP-1 receptor agonists''' '''(GLP-1-RA)''' or '''[[incretin]] mimetics''', are [[agonist]]s of the [[glucagon-like peptide 1 receptor|GLP-1 receptor]]. This class of [[medication]]s is used for the treatment of [[diabetes mellitus type 2|type 2 diabetes]]<ref name=Baggio_2008>{{cite web |url= http://www.medscape.com/viewarticle/578304 |title= Glucagon-like Peptide-1 Analogs Other Than Exenatide |year= 2008 |author= Baggio LL |work= Medscape Diabetes & Endocrinology}}</ref><ref>{{cite journal | vauthors = Ali ES, Hua J, Wilson CH, Tallis GA, Zhou FH, Rychkov GY, Barritt GJ | title = The glucagon-like peptide-1 analogue exendin-4 reverses impaired intracellular Ca(2+) signalling in steatotic hepatocytes | journal = Biochimica et Biophysica Acta (BBA) - Molecular Cell Research | volume = 1863 | issue = 9 | pages = 2135\u20132146 | date = September 2016 | pmid = 27178543 | doi = 10.1016/j.bbamcr.2016.05.006 | doi-access = free }}</ref> Some drugs are also approved for [[obesity]]. One of their advantages over older [[anti-diabetic medication#Secretagogues|insulin secretagogues]], such as [[sulfonylurea]]s or [[meglitinide]]s, is that they have a lower risk of causing [[hypoglycemia]].<ref name=ADA2012>{{cite journal | title = Standards of medical care in diabetes--2012 | journal = Diabetes Care | volume = 35 Suppl 1 | pages = S11\u2013S63 | date = January 2012 | pmid = 22187469 | pmc = 3632172 | doi = 10.2337/dc12-s011 | author1 = American Diabetes Association }}</ref> GLP-1 has a short duration of action, so to overcome this limitation several modifications in either the drugs or the formulations are being developed.<ref>{{cite journal | vauthors = Das A, Geetha KM, Hazarika I |title=Contemporary Updates on the Physiology of Glucagon like Peptide-1 and Its Agonist to Treat Type 2 Diabetes Mellitus |journal=International Journal of Peptide Research and Therapeutics |date=29 August 2019 |volume=26 |issue=3 |pages=1211\u20131221 |doi=10.1007/s10989-019-09927-y |s2cid=202854512 }}</ref>\n\nThe 2022 [[American Diabetes Association|ADA]] standards of medical care in diabetes include GLP-1-RA as a first line pharmacological therapy for type 2 diabetes, specifically in patients with [[atherosclerotic cardiovascular disease]] or [[obesity]].<ref name=\"pmid34964831\">{{cite journal | vauthors = Draznin B, Aroda VR, Bakris G, Benson G, Brown FM, Freeman R, Green J, Huang E, Isaacs D, Kahan S, Leon J, Lyons SK, Peters AL, Prahalad P, Reusch JE, Young-Hyman D | display-authors = 6 | title = 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022 | journal = Diabetes Care | volume = 45 | issue = Suppl 1 | pages = S125\u2013S143 | date = January 2022 | pmid = 34964831 | doi = 10.2337/dc22-S009 | s2cid = 245538347 }}</ref>\n\n==Health effects==\nA 2021 meta-analysis found a 12% reduction in all-cause mortality when GLP-1 analogs are used in the treatment of type 2 diabetes, as well as significant improvements in cardiovascular and renal outcomes.<ref>{{cite journal | vauthors = Sattar N, Lee MM, Kristensen SL, Branch KR, Del Prato S, Khurmi NS, Lam CS, Lopes RD, McMurray JJ, Pratley RE, Rosenstock J, Gerstein HC | display-authors = 6 | title = Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials | journal = The Lancet. Diabetes & Endocrinology | volume = 9 | issue = 10 | pages = 653\u2013662 | date = October 2021 | pmid = 34425083 | doi = 10.1016/s2213-8587(21)00203-5 | s2cid = 237281403 | url = http://eprints.gla.ac.uk/250144/8/250144.pdf }}</ref> A ''[[JAMA (journal)|JAMA]]'' article [[meta-analysis]] in 2018 (covering studies concerning GLP-1 agonists, DPP-4 inhibitors, and [[SGLT2 inhibitor]]s) showed GLP-1 agonists were associated with lower [[stroke]] risk than controls.<ref>{{cite journal | vauthors = Zheng SL, Roddick AJ, Aghar-Jaffar R, Shun-Shin MJ, Francis D, Oliver N, Meeran K | title = Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis | journal = JAMA | volume = 319 | issue = 15 | pages = 1580\u20131591 | date = April 2018 | pmid = 29677303 | pmc = 5933330 | doi = 10.1001/jama.2018.3024 | hdl = 10044/1/60316 }}</ref>\n\nPreclinical research has suggested the possibility that the drugs may increase the risk of pancreatitis and pancreatic cancer.<ref>{{cite journal | vauthors = Pinto LC, Falcetta MR, Rados DV, Leit\u00e3o CB, Gross JL | title = Glucagon-like peptide-1 receptor agonists and pancreatic cancer: a meta-analysis with trial sequential analysis | journal = Scientific Reports | volume = 9 | issue = 1 | pages = 2375 | date = February 2019 | pmid = 30787365 | doi = 10.1038/s41598-019-38956-2 | pmc = 6382780 | bibcode = 2019NatSR...9.2375P }}</ref> Analyses of human trials have not found an increased risk of pancreatitis but are insufficiently powered to rule out an effect on pancreatic cancer.<ref>{{cite journal | vauthors = Forsmark CE | title = Incretins, Diabetes, Pancreatitis and Pancreatic Cancer: What the GI specialist needs to know | journal = Pancreatology | volume = 16 | issue = 1 | pages = 10\u201313 | date = 2016 | pmid = 26795258 | doi = 10.1016/j.pan.2015.11.009 }}</ref><ref name=\"pmid32720500\">{{cite journal | vauthors = Nreu B, Dicembrini I, Tinti F, Mannucci E, Monami M | title = Pancreatitis and pancreatic cancer in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists: an updated meta-analysis of randomized controlled trials | journal = Minerva Endocrinologica | volume =  | issue =  | date = July 2020 | pmid = 32720500 | doi = 10.23736/S0391-1977.20.03219-8 | s2cid = 220839863 }}</ref><ref>{{cite journal | vauthors = Boniol M, Franchi M, Bota M, Leclercq A, Guillaume J, van Damme N, Corrao G, Autier P, Boyle P | display-authors = 6 | title = Incretin-Based Therapies and the Short-term Risk of Pancreatic Cancer: Results From Two Retrospective Cohort Studies | journal = Diabetes Care | volume = 41 | issue = 2 | pages = 286\u2013292 | date = February 2018 | pmid = 29146599 | doi = 10.2337/dc17-0280 | hdl = 10281/184291 | s2cid = 207368560 }}</ref>\n\nStudies in rodents have shown GLP1 mediated [[Medullary thyroid cancer|thyroid c-cell hyperplasia]].<ref name=\"pmid20203154\">{{cite journal | vauthors = Bjerre Knudsen L, Madsen LW, Andersen S, Almholt K, de Boer AS, Drucker DJ, Gotfredsen C, Egerod FL, Hegelund AC, Jacobsen H, Jacobsen SD, Moses AC, M\u00f8lck AM, Nielsen HS, Nowak J, Solberg H, Thi TD, Zdravkovic M, Moerch U | display-authors = 6 | title = Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation | journal = Endocrinology | volume = 151 | issue = 4 | pages = 1473\u20131486 | date = April 2010 | pmid = 20203154 | doi = 10.1210/en.2009-1272 | s2cid = 20934882 }}</ref>\n\nA 2020 Cochrane systematic review did not find enough evidence of reduction of all-cause mortality, serious adverse events, cardiovascular mortality, non-fatal [[myocardial infarction]], non-fatal [[stroke]], [[Chronic kidney disease|end-stage renal disease]] nor health-related quality of life when comparing [[metformin]] monotherapy to Glucagon-like peptide 1 analogues in the treatment of type 2 diabetes.<ref>{{cite journal | vauthors = Gnesin F, Thuesen AC, K\u00e4hler LK, Madsbad S, Hemmingsen B | title = Metformin monotherapy for adults with type 2 diabetes mellitus | journal = The Cochrane Database of Systematic Reviews | volume = 2020 | issue = 6 | pages = CD012906 | date = June 2020 | pmid = 32501595 | pmc = 7386876 | doi = 10.1002/14651858.CD012906.pub2 |collaboration = Cochrane Metabolic and Endocrine Disorders Group }}</ref>\n\n==Approved==\n*[[exenatide]] (brand names Byetta and Bydureon, manufactured by [[AstraZeneca]]), approved in 2005/2012\n*[[liraglutide]] (Victoza for diabetes, Saxenda for obesity, manufactured by [[Novo Nordisk]]), approved in 2010<ref>{{cite web |url=https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm198638.htm |title=FDA Approves New Treatment for Type 2 Diabetes|website=[[Food and Drug Administration]]}}</ref>\n*[[lixisenatide]] (Lyxumia in Europe, Adlyxin in the United States, manufactured by [[Sanofi]]), approved in 2016<ref>{{cite web |url=https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm513602.htm |title=FDA approves Adlyxin to treat type 2 diabetes|website=[[Food and Drug Administration]]|date=2019-09-10}}</ref>\n*[[albiglutide]] (Tanzeum, manufactured by [[GlaxoSmithKline|GSK]]), approved in 2014<ref>{{cite web |url=http://www.medscape.com/viewarticle/823645 |title=FDA Approves Weekly Injectable Diabetes Drug: Albiglutide}}</ref>\n*[[dulaglutide]] (Trulicity, manufactured by [[Eli Lilly and Company|Eli Lilly]]), approved in 2014<ref>{{cite web |url=https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm415180.htm |title=FDA Approves Weekly Injectable Diabetes Drug: Dulaglutide|website=[[Food and Drug Administration]]}}</ref>\n*[[semaglutide]] (Ozempic and Rybelsus for diabetes, Wegovy for obesity, manufactured by Novo Nordisk), approved in 2017<ref>[http://www.medscape.com/viewarticle/803916_5 Longer Acting GLP-1 Receptor Agonists and the Potential for Improved Cardiovascular Outcomes. 2013]</ref>\n*[[tirzepatide]] (Mounjaro, manufactured by Eli Lilly), approved in 2022<ref>{{cite journal | vauthors = Fr\u00edas JP, Davies MJ, Rosenstock J, P\u00e9rez Manghi FC, Fern\u00e1ndez Land\u00f3 L, Bergman BK, Liu B, Cui X, Brown K | display-authors = 6 | title = Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes | journal = The New England Journal of Medicine | volume = 385 | issue = 6 | pages = 503\u2013515 | date = August 2021 | pmid = 34170647 | doi = 10.1056/NEJMoa2107519 | s2cid = 235635529 | author10 = SURPASS-2 Investigators }}</ref>\n\n==Under investigation==\n*[[taspoglutide]], phase III halted Sept 2010<ref name=Baggio_2008/>\n*efpeglenatide<ref>{{cite journal | vauthors = Gerstein HC, Sattar N, Rosenstock J, Ramasundarahettige C, Pratley R, Lopes RD, Lam CS, Khurmi NS, Heenan L, Del Prato S, Dyal L, Branch K | display-authors = 6 | title = Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes | journal = The New England Journal of Medicine | volume = 385 | issue = 10 | pages = 896\u2013907 | date = September 2021 | pmid = 34215025 | doi = 10.1056/NEJMoa2108269 | s2cid = 235723092 | url = http://eprints.gla.ac.uk/246785/1/246785.pdf }}</ref>\n\n==Mechanism==\nThese agents work by activating the GLP-1R, rather than inhibiting the breakdown of GLP-1 as do [[dipeptidyl peptidase-4 inhibitor|DPP-4 inhibitors]], and are generally considered more potent.<ref>{{cite web |url=http://www.medscape.com/viewarticle/824247 |title=GLP-1 Receptor Agonists vs. DPP-4 Inhibitors for Type 2 Diabetes}}</ref>\n\n== References ==\n{{Reflist}}\n\n{{Oral hypoglycemics and insulin analogs}}\n\n[[Category:Glucagon-like peptide-1 receptor agonists| ]]"}